CSS
CORT icon

Cubist Systematic Strategies’s Corcept Therapeutics CORT Stock Holding History

Cubist Systematic Strategies’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-351,374
Closed -$8.85M – 3157
2024
Q1 		$8.85M Buy
351,374
+118,690
+51% +$2.8M 0.05% 596
2023
Q4 		$7.56M Sell
232,684
-55,494
-19% -$1.52M 0.05% 613
2023
Q3 		$7.85M Buy
288,178
+188,189
+188% +$5.45M 0.06% 500
2023
Q2 		$2.22M Sell
99,989
-4,037
-4% -$92.9K 0.01% 1409
2023
Q1 		$2.25M Sell
104,026
-159,472
-61% -$3.5M 0.01% 1578
2022
Q4 		$5.35M Buy
263,498
+142,044
+117% +$3.56M 0.03% 956
2022
Q3 		$3.11M Sell
121,454
-53,419
-31% -$1.43M 0.02% 1554
2022
Q2 		$4.16M Sell
174,873
-131,139
-43% -$2.86M 0.03% 1159
2022
Q1 		$6.89M Buy
306,012
+154,184
+102% +$3.28M 0.06% 505
2021
Q4 		$3.01M Buy
151,828
+96,570
+175% +$1.96M 0.03% 1019
2021
Q3 		$1.09M Buy
55,258
+29,111
+111% +$609K 0.01% 1455
2021
Q2 		$575K Buy
26,147
+17,718
+210% +$394K 0.01% 1915
2021
Q1 		$201K Sell
8,429
-810
-9% -$21.6K ﹤0.01% 2473
2020
Q4 		$242K Sell
9,239
-21,196
-70% -$447K ﹤0.01% 2141
2020
Q3 		$530K Sell
30,435
-92,293
-75% -$1.47M 0.01% 1710
2020
Q2 		$2.06M Buy
122,728
+35,085
+40% +$493K 0.04% 775
2020
Q1 		$1.04M Sell
87,643
-13,780
-14% -$171K 0.03% 806
2019
Q4 		$1.23M Buy
101,423
+3,847
+4% +$53.6K 0.02% 1033
2019
Q3 		$1.38M Buy
97,576
+71,429
+273% +$878K 0.03% 813
2019
Q2 		$292K Sell
26,147
-25,851
-50% -$288K 0.01% 1822
2019
Q1 		$610K Buy
51,998
+15,619
+43% +$194K 0.02% 1059
2018
Q4 		$486K Buy
+36,379
New +$481K 0.02% 992
2018
Q1 		– Sell
-15,714
Closed -$284K – 1868
2017
Q4 		$284K Sell
15,714
-9,366
-37% -$170K 0.02% 1285
2017
Q3 		$484K Sell
25,080
-9,517
-28% -$142K 0.03% 846
2017
Q2 		$408K Sell
34,597
-10,623
-23% -$115K 0.03% 850
2017
Q1 		$496K Sell
45,220
-25,663
-36% -$225K 0.04% 643
2016
Q4 		$515K Buy
+70,883
New +$555K 0.04% 653
2015
Q4 		– Sell
-10,311
Closed -$39K – 1777
2015
Q3 		$39K Buy
+10,311
New +$52.3K ﹤0.01% 1742

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Cubist Systematic Strategies's CORT Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 351,374 shares — an estimated $8.85M sold.

Cubist Systematic Strategies first reported a position in CORT in Q3 2015 and held it in 28 quarters. The position peaked at $8.85M in Q1 2024. 286 funds tracked by Wall St. Rank hold CORT as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 351,374 Corcept Therapeutics shares in Q2 2024, an estimated $8.85M.
  • Cubist Systematic Strategies first reported a position in Corcept Therapeutics in Q3 2015 and held it in 28 quarters.
  • Cubist Systematic Strategies's Corcept Therapeutics position peaked at $8.85M in Q1 2024.
  • 286 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.